Ohio Supreme Court Ties CAT to Actual Receipts, Not Invoice List Prices
Ohio's Supreme Court unanimously held that a drug manufacturer's Commercial Activity Tax base is the amount it actually received, not the higher list price on invoices. The court affirmed the Board of Tax Appeals and rejected the Tax Commissioner's attempt to assess tax on chargebacks treated as expenses. The case involved Perrigo's distributor sales, where chargebacks reduced payments to net amounts.
Perrigo makes generic prescription medicines and sells through wholesale distributors that supply retailers such as CVS and Walmart. It bills distributors at list price but separately negotiates lower retail prices; distributors then remit the net amount after subtracting chargebacks. Those chargebacks are contractually required, cover roughly 97% of distributor sales, and are usually processed within two days. Perrigo booked revenue net of chargebacks for accounting and federal tax reporting.
After an audit of 2016–2018, Ohio’s tax commissioner assessed additional CAT by treating chargebacks as expenses. The Board of Tax Appeals reversed, and the Ohio Supreme Court, in an opinion by Justice DeWine, unanimously affirmed.
The ruling may affect Ohio businesses whose receipts are reduced by contractual adjustments before payment, especially manufacturers and distributors using chargeback arrangements. It could reduce uncertainty over CAT exposure and may influence how tax auditors treat invoice list prices versus actual funds received. Consumers and retailers may see indirect effects if pricing and distribution practices shift, though the immediate impact is likely concentrated among tax, finance, and compliance professionals.